Ilunocitinib (Zenrelia): A Clinical Guide to the Once-Daily JAK Inhibitor for Canine Atopic Dermatitis

Bottom line

Ilunocitinib (Zenrelia, Elanco) is a once-daily oral Janus kinase (JAK) inhibitor approved by the FDA in 2024 for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age [1]. Unlike oclacitinib it has no twice-daily induction phase, and a 2025 head-to-head trial found it maintained lower pruritus and lesion scores from day 28 onward [2]. Its defining prescribing constraint is a boxed warning requiring dogs to be current on modified-live/attenuated vaccines before starting [3].

Drug facts

Class and mechanism. A small-molecule JAK inhibitor with high in vitro potency across JAK1, JAK2, and TYK2 and lesser JAK3 activity, but with an antipruritic effect driven predominantly by JAK1-dependent signalling [1]. Blocking JAK1 interrupts the cascades for the key pruritogenic and allergic cytokines in canine atopic dermatitis — chiefly IL-31, plus IL-4, IL-13, and IL-2/IL-6 family signalling — the same target space as oclacitinib.

Dose and formulation. 0.6 to 0.8 mg/kg orally once daily, with or without food [1], in scored 4.8, 6.4, 8.5, and 15 mg tablets. There is no oclacitinib-style twice-daily loading period, removing the induction-to-maintenance transition that can trigger rebound [2].

Indication and cautions. FDA approved in September 2024 for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age [1] — the second JAK inhibitor licensed for this indication. It is contraindicated in dogs under 12 months or with serious infections, and being immunosuppressive warrants caution in dogs with a history of neoplasia, demodicosis, or recurrent infection; safety is not established in breeding, pregnant, or lactating dogs [1].

Efficacy and onset of action

Onset is rapid — an antipruritic effect appears within the first 24 hours of the first dose [1][4]. In the pivotal multicentre, double-masked, randomised, placebo-controlled field trial (268 dogs, 25 clinics, 112 days), 83% of ilunocitinib-treated dogs met the pruritus treatment-success criterion versus 31% on placebo, with sustained improvement in owner-assessed pruritus (PVAS) and investigator-scored lesions (CADESI-04); a separate placebo-controlled allergic-dermatitis field trial reproduced the same result [4][5].

Head-to-head versus oclacitinib

The 2025 randomised comparative trial of ilunocitinib versus oclacitinib in atopic dogs is the key evidence [2]. Through the first two weeks the drugs behaved almost identically — PVAS and CADESI-04 reductions from day 0 to day 14 were similar — then diverged: between day 14 and day 28 mean PVAS rose on oclacitinib but kept falling on ilunocitinib, and from day 28 through day 112 both scores were significantly lower for ilunocitinib (p ≤ 0.003 and p ≤ 0.023) [2]. The likely driver is regimen, not potency: oclacitinib steps down from twice- to once-daily at day 14, where a subset of dogs lose control, whereas ilunocitinib never steps down. More ilunocitinib dogs also reached remission of pruritus (PVAS < 2) by day 7 and lesions (CADESI-04 < 10) by day 14 [2].

The boxed warning and vaccination timing

Zenrelia carries a boxed warning centred on vaccination [1][3]. Dogs should be current on modified-live/attenuated (and other core) vaccines before starting, completing the series an appropriate interval before the first dose. Discontinue Zenrelia at least 28 days to 3 months before a planned vaccination, and withhold it for at least 28 days afterward [3]. JAK inhibition blunts the immune response, so vaccinating on active therapy risks inadequate protection. The label originally also warned of fatal vaccine-induced disease from a lab study in unvaccinated dogs dosed at three times label; following FDA review of post-marketing data, that language was removed in a 2025 revision while the boxed vaccination-timing guidance was retained [3]. Treat the interval as a hard planning constraint settled at the consult.

Adverse events and monitoring

At the therapeutic (1x) dose ilunocitinib is generally well tolerated, with a field profile similar to placebo and to oclacitinib [2][4]; the commonest signs are gastrointestinal (soft stool/diarrhoea, occasional vomiting) and urinary tract infections, with GI rates comparable to placebo by day 28 [4]. Dose-dependent decreases in erythrocytic parameters appeared only at exaggerated multiples of the label dose in target-animal safety work, underpinning the class infection/immunosuppression caution [1]. There is no mandated laboratory schedule as with ciclosporin, but a reasonable approach includes baseline and periodic exams plus CBC/biochemistry in older or long-term patients, with vigilance for recurrent infection, worsening demodicosis, or new masses.

Clinical positioning

Versus oclacitinib (Apoquel). Same class and comparable onset, but ilunocitinib is once-daily with no step-down, and the head-to-head data favour it on sustained control from day 28 onward [2]. The trade-off is the vaccination boxed warning, which oclacitinib does not carry.

Versus lokivetmab (Cytopoint). A monthly injectable anti-IL-31 monoclonal antibody with an excellent safety margin and no immunosuppression — attractive for young dogs, comorbid infection/neoplasia risk, or owners preferring injections. Ilunocitinib offers broader cytokine blockade and oral flexibility at the cost of immunomodulation and the vaccination constraint.

Versus ciclosporin. A proven non-JAK option where JAK inhibition is undesirable, but onset is markedly slower (weeks). Overall, ilunocitinib is a strong first-line choice for adult, appropriately vaccinated dogs — with vaccination status and infection/neoplasia risk the decisive gating questions.

Frequently Asked Questions

What is ilunocitinib (Zenrelia) and how does it work?

Ilunocitinib is a once-daily oral Janus kinase (JAK) inhibitor from Elanco. It blocks JAK-dependent signalling — predominantly JAK1 — for the cytokines driving canine atopic dermatitis, chiefly IL-31 plus IL-4 and IL-13, interrupting the itch-and-inflammation cascade [1].

How is Zenrelia dosed, and is there a loading phase like Apoquel?

The dose is 0.6 to 0.8 mg/kg orally once daily, with or without food, in adult dogs [1]. Unlike oclacitinib (Apoquel), there is no twice-daily induction phase — dogs start and stay on the once-daily regimen, which likely explains its better sustained control after day 14 [2].

How quickly does ilunocitinib start working?

Rapidly — an antipruritic effect appears within the first 24 hours of the first dose, with many dogs reaching meaningful pruritus reduction within the first week [1][4], placing it in the fast-onset tier with oclacitinib and lokivetmab.

Is ilunocitinib more effective than oclacitinib?

Through two weeks they perform similarly. In the 2025 head-to-head trial, PVAS and CADESI-04 reductions matched from day 0 to day 14, but from day 28 through day 112 both scores were significantly lower with ilunocitinib (p ≤ 0.003 and p ≤ 0.023), with comparable safety [2].

What is the boxed warning about vaccination?

Zenrelia carries a boxed warning on vaccination because JAK inhibition blunts the immune response [1][3]. Dogs should be current on modified-live/attenuated and core vaccines before starting; discontinue Zenrelia at least 28 days to 3 months before a planned vaccination and withhold it for at least 28 days afterward [3].

Can I vaccinate a dog that is on Zenrelia?

Not while therapy is active. Complete vaccines before starting, then, when a booster is due, stop Zenrelia within the labeled pre-vaccination window and resume no sooner than 28 days after [3]. For young or incompletely vaccinated dogs, lokivetmab or a non-JAK option may be more practical.

What are the common side effects and what monitoring is recommended?

At the label dose it is generally well tolerated, with a field safety profile similar to placebo and to oclacitinib [2][4]; most reported signs are mild GI upset and urinary tract infections. As an immunomodulator it warrants vigilance for infection, worsening demodicosis, and new neoplasia, with periodic exams and CBC/biochemistry in long-term or older patients [1].

Which dogs should not receive ilunocitinib?

Avoid it in dogs under 12 months or with serious active infections, and use caution in dogs with a history of neoplasia, demodicosis, or recurrent deep infection. Safety in breeding, pregnant, or lactating dogs is not established, and incomplete vaccination status is a relative barrier because of the boxed warning [3].